These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17034582)

  • 1. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.
    Morgan BP; Chamberlain-Banoub J; Neal JW; Song W; Mizuno M; Harris CL
    Clin Exp Immunol; 2006 Nov; 146(2):294-302. PubMed ID: 17034582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.
    Chamberlain-Banoub J; Neal JW; Mizuno M; Harris CL; Morgan BP
    Clin Exp Immunol; 2006 Nov; 146(2):278-86. PubMed ID: 17034580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell surface complement regulators moderate experimental myasthenia gravis pathology.
    Kusner LL; Halperin JA; Kaminski HJ
    Muscle Nerve; 2013 Jan; 47(1):33-40. PubMed ID: 23042232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
    Soltys J; Halperin JA; Xuebin Q
    J Neuroimmunol; 2012 Mar; 244(1-2):63-9. PubMed ID: 22325826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Morgan BP; Christadoss P
    J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
    Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
    J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
    Kaminski HJ; Kusner LL; Richmonds C; Medof ME; Lin F
    Exp Neurol; 2006 Dec; 202(2):287-93. PubMed ID: 16859686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulation in experimental autoimmune myasthenia gravis--about T cells, antibodies, and endplates.
    De Baets M; Stassen M; Losen M; Zhang X; Machiels B
    Ann N Y Acad Sci; 2003 Sep; 998():308-17. PubMed ID: 14592888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.
    Lin F; Kaminski HJ; Conti-Fine BM; Wang W; Richmonds C; Medof ME
    J Clin Invest; 2002 Nov; 110(9):1269-74. PubMed ID: 12417565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis.
    Qi H; Tüzün E; Allman W; Saini SS; Penabad ZR; Pierangeli S; Christadoss P
    J Neuroimmunol; 2008 May; 196(1-2):101-6. PubMed ID: 18455242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
    Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
    Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
    Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
    J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced complement activation and MAC formation accelerates severe COVID-19.
    Ellsworth CR; Chen Z; Xiao MT; Qian C; Wang C; Khatun MS; Liu S; Islamuddin M; Maness NJ; Halperin JA; Blair RV; Kolls JK; Tomlinson S; Qin X
    Cell Mol Life Sci; 2024 Sep; 81(1):405. PubMed ID: 39284944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.
    Lin F; Salant DJ; Meyerson H; Emancipator S; Morgan BP; Medof ME
    J Immunol; 2004 Feb; 172(4):2636-42. PubMed ID: 14764738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of complement in experimental autoimmune myasthenia gravis.
    Kusner LL; Kaminski HJ
    Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.
    Engel AG; Sakakibara H; Sahashi K; Lindstrom JM; Lambert EH; Lennon VA
    Neurology; 1979 Feb; 29(2):179-88. PubMed ID: 571062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.